Cost Effectiveness Analysis of Routine Use of Genotypic Antiretroviral Resistance Testing after Failure of Antiretroviral Treatment for HIV

Abstract

Routine use of GART after treatment failures is cost effective. GART prior to the first HAART would be equally cost effective if it could lower the probability of first HAART failure by approximately a third.